General Counsel & Secretary Soares Karen covered exercise/tax liability with 28,553 shares, decreasing direct ownership by 2% to 1,357,508 units (SEC Form 4)

$CLOV
Medical Specialities
Health Care
Get the next $CLOV alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Soares Karen

(Last) (First) (Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
30 MONTGOMERY STREET

(Street)
JERSEY CITY NJ 07302

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
01/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 01/31/2025 F 28,553(1) D $4.39 1,357,508 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations upon the vesting, on January 31, 2025, of 12.5% of the original number of time-based restricted stock units ("RSUs") granted to the Reporting Person on October 31, 2023, and timely reported on a Form 4 filed on November 2, 2023. The remaining RSUs vest in three equal quarterly installments, with the final vesting date occurring on October 31, 2025, subject to the continued service of the Reporting Person on each such vesting date.
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Karen M. Soares 02/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CLOV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLOV

DatePrice TargetRatingAnalyst
12/17/2024$6.00Buy
Craig Hallum
10/7/2024$4.00Neutral
UBS
2/25/2022$3.00 → $2.50Market Perform
SVB Leerink
2/2/2022$7.00 → $3.00Underperform → Market Perform
Cowen & Co.
2/2/2022$6.00Buy
Canaccord Genuity
1/19/2022$3.00Market Perform
SVB Leerink
1/10/2022$9.00 → $3.50Neutral
Citigroup
1/7/2022$9.00 → $3.50Neutral → Underperform
Credit Suisse
More analyst ratings

$CLOV
Press Releases

Fastest customizable press release news feed in the world

See more
  • Counterpart Health Partners with Google Cloud to Improve Clinical Data Access for Physicians

    WILMINGTON, Del., March 03, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced it has partnered with Google Cloud to integrate Vertex AI Search into its flagship technology, Counterpart Assistant. This innovation gives providers on Counterpart Assistant a generative AI (gen AI) search experience across the breadth of a patient's digital health record to provide contextualized insights, and to make it easier to deliver value-based care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). Physicians struggle to access and synthesize the vast amounts of data within

    $CLOV
    Medical Specialities
    Health Care
  • Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance

    Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpointInsurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointAdjusted EBITDA profitability between $45 million and $70 millionAdjusted Net income between

    $CLOV
    Medical Specialities
    Health Care
  • Clover Health to Participate in Upcoming Investor Conferences

    WILMINGTON, Del., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced its participation in the following investor conferences: CFO, Peter Kuipers, will participate in the 2025 Jefferies Value-Based Healthcare Summit on Monday, March 10, 2025.CFO, Peter Kuipers, will present at the 2025 Leerink Global Healthcare Conference on Tuesday, March 11, 2025, at 8:00 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A session will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/. About Clover Health:Clover Health (NASDAQ:CLOV) is a physician enablement technology

    $CLOV
    Medical Specialities
    Health Care

$CLOV
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CLOV
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$CLOV
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CLOV
SEC Filings

See more

$CLOV
Leadership Updates

Live Leadership Updates

See more
  • Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer

    FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart's clinical strategy and product roadmap for Counterpart Assistant, the company's proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). David Tsay is a distinguished physician executive with deep expertise and over two decades of ex

    $CLOV
    Medical Specialities
    Health Care
  • Clover Health Appoints Seasoned Healthcare Executive as Chief Operating Officer for Medicare Advantage Operations

    FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation. Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operation

    $CLOV
    Medical Specialities
    Health Care
  • Thomas L. Tran, Former Chief Financial Officer of Molina Healthcare, Joins Clover Health's Board of Directors

    FRANKLIN, Tenn., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced it has appointed Thomas L. Tran to the Company's Board of Directors (the "Board"), and as a member of the Audit Committee. "Tom Tran's appointment to our Board marks a significant enhancement to our strategic financial planning and execution capabilities. With his impressive track record at the helm of finance at public managed care organizations, Tom is uniquely qualified to help guide Clover Health as we advance o

    $CLOV
    Medical Specialities
    Health Care

$CLOV
Financials

Live finance-specific insights

See more
  • Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance

    Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpointInsurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointAdjusted EBITDA profitability between $45 million and $70 millionAdjusted Net income between

    $CLOV
    Medical Specialities
    Health Care
  • Clover Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

    WILMINGTON, Del., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced that it will report fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on February 27, 2025, to discuss Clover Health's fourth quarter and full year 2024 business and financial results. Fourth Quarter and Full Year 2024 Conference Call and Webcast Details: What: Clover Health's Fourth Quarter and Full Year 2024 Earnings Conference CallWhen: Thursday, February 27, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via tele

    $CLOV
    Medical Specialities
    Health Care
  • Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership

    Delivers 9% Total Revenue growth year-to-date compared to prior year period Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117.4 million year-over-year and year-to-date Adjusted EBITDA by $87.2 million year-over-year Increases Full-Year 2024 guidance midpoint to target updated range of Adjusted EBITDA profitability of $55 million - $65 million, strongly positioning the Company to invest in membership growth opportunity for 2025 FRANKLIN, Tenn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today reported financial results for the third quarter 2024. Management will host a co

    $CLOV
    Medical Specialities
    Health Care

$CLOV
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more

$CLOV
Insider purchases explained

Analytical look into recent insider purchases

See more
  • Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    $CLOV
    Medical Specialities
    Health Care